Drug Discovery & DDS– category –
-
Wave Life Sciences Reports Positive RNA Editing Clinical Data for WVE-006 in Alpha-1 Antitrypsin Deficiency (AATD)
BioPharm International USA Overview Wave Life Sciences announced favorable clinical data from the RestorAATion-2 trial of WVE-006, an RNA editing therapeutic for Alpha-1 Antitrypsin Deficiency (AATD). WVE-006, a GalNAc-conjugated RNA edi... -
Eli Lilly Acquires Engage Biologics for Up to $202 Million to Strengthen Non-Viral DNA Delivery Platform
GuruFocus USA Overview Eli Lilly has agreed to acquire Engage Biologics for up to $202 million, aiming to leverage Engage’s innovative non-viral DNA delivery platform and accelerate the development of next-generation gene therapies. Enga... -
Isomorphic Labs Secures $2.1 Billion to Scale AI Drug Discovery Engine, Eyes First AI-Designed Drug in Human Trials by Year-End
AI Healthcare News USA Overview Isomorphic Labs, Alphabet's AI drug discovery arm, has raised a staggering $2.1 billion to expand its "IsoDDE" AI engine. Leveraging AI in conjunction with AlphaFold 3, the company develops a platform to p... -
Immunai and AstraZeneca Expand Oncology AI Partnership for Third Time, Valued at Up To $37.5 Million
WTWH Media USA Overview Immunai, a startup building foundation models for the human immune system, has announced a third expansion of its oncology partnership with AstraZeneca, entitling Immunai to up to $37.5 million through 2027. This ... -
Incyte and Genesis Molecular AI Expand Partnership to Accelerate AI-Driven Drug Discovery with Over $1 Billion in Milestones
Forbes USA Overview Incyte has significantly expanded its strategic collaboration with Genesis Molecular AI, integrating AI platforms with proprietary experimental data to accelerate novel molecule discovery. This enhanced partnership, p... -
Lilly’s Retatrutide Achieves Unprecedented Weight Loss in Pivotal Phase 3 Obesity Trial
Eli Lilly and Company USA Overview Eli Lilly's triple-agonist retatrutide, targeting GIP, GLP-1, and glucagon receptors, demonstrated powerful efficacy in its pivotal Phase 3 TRIUMPH-1 trial for obesity. Patients receiving the highest do... -
Drug Discovery & DDS Weekly Report May 18, 2026
📄 Weekly Report May 18, 2026 (PDF) — Download Weekly Report May 18, 2026 (PDF) — DownloadDownload 🎙 Podcast May 17, 2026 (MP3) — Play & Download DrugDiscovery_DDSEnglishPodcast_20260517_sample.mp3Download -
Daiichi Sankyo Records Significant Loss Due to ADC Supply ‘Miscalculation’ Despite Strong Enhertu Sales, Raising Risk Management Questions
東洋経済オンライン Japan Overview Japanese pharmaceutical giant Daiichi Sankyo reported a substantial operating profit decrease for FY2025 despite record sales, attributing a 169.5 billion yen loss provision to compensation for Antibody-... -
Curanex Pharmaceuticals Reports Q1 2026 Progress, Phyto-N Advances Towards FDA IND Submission for Ulcerative Colitis and Pipeline Expands to Cancer Cachexia
Taiwan News Taiwan Overview US-based Curanex Pharmaceuticals provided a Q1 2026 update, focusing on its lead drug candidate, Phyto-N. The company is advancing Phyto-N towards a planned Investigational New Drug (IND) submission to the U.S... -
Veritas In Silico Advances mRNA-Targeted Small Molecule Drug Discovery with AI Platform ‘aibVIS,’ Bolstering European Collaborations
Investing.com (Fisco提供) Japan Overview Japanese biotech Veritas In Silico (VIS) is spearheading mRNA-targeted small molecule drug discovery using its proprietary AI platform, "aibVIS." This platform integrates in silico RNA structure a...
